Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

globenewswire.com
INAB The article announces IN8bio's participation in an investment conference, which is a standard corporate event. No new information about the company's performance or prospects is provided, making the sentiment neutral.

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and Co-Founder, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, on Monday, September 14, 2026, in New York.

Mr. Ho and members of the IN8bio management team will host one-on-one meetings with investors throughout the conference.

H.C. Wainwright 28th Annual Global Investment Conference

Date: Monday, September 14, 2026

Time: 10:00 a.m. ET

Format: Fireside Chat

Presenter: William Ho, Chief Executive Officer and Co-Founder

Location: Kennedy II, 4th Floor, Lotte New York Palace Hotel, New York City

Webcast: Webcast Link

A live webcast of the presentation will be available through the Investors section of IN8bio’s website. A replay will be available following the event.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.

Patrick McCall

646.933.5603

pfmccall@IN8bio.com

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744

kimberly.ha@kkhadvisors.com